HYDROGEN-MOBILITY-EUROPE
A flagship project for hydrogen mobility involving nearly 50 organisations at the forefront of the sector has today published its final report detailing the key findings and learnings. The findings are released at a crucial time as the European Green Deal seeks a 90% reduction in transport related emissions by 2050.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005025/en/
Hydrogen Mobility Europe (H2ME) has completed its first phase and compiled a rich dataset since initiating in 2016: 630 hydrogen fuel cell electric vehicles have been deployed in 10 countries and 37 new hydrogen refuelling stations installed in 8 countries, achieving 14.5 million km driven and 147 tonnes of hydrogen dispensed across 68,000 refuelling events. It is the largest European deployment for hydrogen mobility to date and demonstrates the commercial potential to rollout fuel cell electric vehicles (FCEVs) and hydrogen refuelling stations (HRS) for large and small fleets.
Following the conclusion of its initial phase, H2ME recommends national and international incentives that ensure the dispensed cost of low carbon hydrogen is competitive for vehicle operators to create a level playing field with other zero emission vehicles. National, regional, and local policies that ensure continued development of the industry are also recommended. The expansion of hydrogen infrastructure as a result of H2ME, co-funded by the FCH-JU, means more FCEVs now have access to refuelling stations however the limited infrastructure prevents full operational advantages of FCEVs being realised.
Incentives such as purchase grants and tax exemptions will unlock demand from vehicle operators and bring market confidence to vehicle suppliers. Similarly, financial support applied per unit (kg) of hydrogen sold, similar to the feed in tariffs which were applied to stimulate early renewable energy uptake, will lower the price of green hydrogen at the pump. This will enable high utilisation of refuelling stations, which strengthens its business case, demonstrated by clusters of captive fleets with high mileage and heavy-duty cycles as they have significantly lower costs per kilogram of hydrogen.
The second phase of deployment will focus on developing state of the art refuelling stations, increased options for producing green hydrogen, and targeting a wider range of vehicles (from light duty to heavy duty vehicles). The lessons from phase one show that future hydrogen mobility strategies should focus more on high mileage and heavy-duty applications to provide the anchor demand for new installations. This will provide a stronger business case to the HRS operators.
Hydrogen could play a key role in enabling high mileage applications can transition to zero emission as these applications have specific operational needs such as long range and short refuelling time, that can be met by FCEVs. The overall cost of operating FCEVs in these fleets is expected to decrease rapidly in the coming years. For example, an analysis from the ZEFER project found that for high mileages applications such as taxis, and with hydrogen at €7,5/kg, FCEVs can reach parity on a total cost of ownership basis with petrol/diesel hybrids in the next 5 years.
In Denmark three Hyundai ix35 FCEVs are used by the Municipality of Copenhagen for a variety of duties as part of H2ME. They average 120 km travelled per day, with recorded distances up to 500 km in a single day, and have access to three refuelling stations within driving range. Well-to-wheel (WTW) emissions from FCEVs in Denmark are calculated at 20 gCO2e/km, compared to 34 gCO2e/km for a battery electric vehicle, 47 gCO2e/km for a battery electric SUV and 217 gCO2e/km for a diesel comparator. The use of 100% green certified electrolytic hydrogen is key to the low emissions, however FCEVs still achieve significantly lower WTW emissions than diesel or gasoline vehicles even if using hydrogen derived from fossil fuels. Similar analysis conducted in Germany and France found that FCEVs achieve significant emission savings compared to diesel or gasoline vehicles, even if using fossil-derived hydrogen, and can be even more significantly when using low carbon or green hydrogen.
The fuel cell electric vehicles deployed have completed up to 600 km of driving range on a single tank, and prove reliable with over 99% availability over their operational usage since 2016. The confirmation of technology readiness, emerging business cases and customer proposition in the project shows a path towards commercialisation.
With increasing needs for zero emissions mobility solutions to achieve environmental targets, and economics expecting to improve rapidly at scale, there is a strong case to support the commercial rollout for hydrogen mobility.
Bart Biebuyck, Executive Director at Fuel Cells and Hydrogen Joint Undertaking (FCH JU), said : “The first phase of H2ME has demonstrated that light duty hydrogen fuel cell vehicles are performant and nearing market competition with other zero emissions vehicles for high mileage applications, like taxi fleets. In addition, our flagship project was successful in supporting the onset of a European H2 infrastructure for road transport. Today, Europe has a card to play: By integrating these learnings into the heavy duty truck sector, it can capitalise on best practices of vehicles fleets and infrastructure management, making an essential contribution to a green post-Covid recovery of our economy”.
Ben Madden, Director at Element Energy, said: “We are pleased to share the results and findings of the H2ME 1 project. This project would not have been possible without the support from the FCH JU and commitment of all partners involved. Grants to support early stage commercial deployments are a critical step in the path towards commercialisation and will remain one of the key financial tools at the European level in the coming year to develop solutions for zero-emission mobility. Element Energy is very proud to have coordinated this project and to continue supporting the largest hydrogen mobility initiative in Europe.”
Dr Duncan Yellen, Managing Director at ITM Motive, said: “Participation in the H2ME project has been invaluable in providing insights into both the engineering and customer requirements for our future build programme. Thanks to the learning provided here and through other funded projects we are confident in our ability to provide the best possible designs for building the next generation of Hydrogen Refuelling Stations across the UK to match the needs of heavy duty vehicles, high use car fleets and rail.”
Nikolas Iwan, CEO of H2 Mobility, said: “20 of the more than 90 stations in Germany have been built in the H2ME project. We are proud to be partner in the largest European hydrogen mobility initiative. Collaboration is the key to a successful mobility transition, especially in the next phase were rules and regulations have to be set for the light and heavy duty transport sector.”
Anna Margrét Kornelíusdóttir, Project Manager at Icelandic New Energy Ltd, said: "The Nordic countries have long had a faith in clean hydrogen produced from their abundant renewable energy resources. Our governments have made this clear by implementing generous economic incentives and ambitious strategies.
“H2ME has demonstrated the use and reliability of hydrogen and fuel cell technology for passenger vehicles across Europe and proven the feasibility of hydrogen as a transport fuel.
“Amid rising pressure to reach decarbonisation goals, hydrogen technology represents a low carbon and low emission energy solution that can play a vital role in the next steps addressing a transition to clean energy, not only for passenger vehicles, but also heavy-duty trucks, marine vessels and even aviation”.
- Ends -
Notes to Editor
Download the full report here: https://h2me.eu/wp-content/uploads/2021/01/H2ME_Emerging-Conclusions2020.pdf
Image: https://we.tl/t-rvTibkH4Bz
Caption: 37 new hydrogen refuelling stations have been installed in 8 countries as part of the H2ME project
About H2ME
This €170 million demonstration project is co-funded with €67 million from the Fuel Cells and Hydrogen Joint Undertaking (FCH JU), a public-private partnership supporting fuel cell and hydrogen energy technologies in Europe.
Partners include project lead Element Energy, alongside AGA, Air Liquide, AREVA H2GEN, Audi, BOC, BMW, Cenex, City of Copenhagen (Kobenhavns Kommune), Communauté d’Agglomération Sarreguemines Confluence, CNR, Daimler AG, Danish Hydrogen Fuel, EIFER, GNVERT, H2 Mobility Deutschland, Honda, Hydrogen Denmark (Brintbranchen), Hydrogene de France, hySOLUTIONS, Hyundai, Icelandic New Energy Ltd, Intelligent Energy, Islenska Vetnisfelagid (H2 Iceland), Kerkhof, ITM Power, Linde AG, McPhy Energy, Michelin, Nel Hydrogen, Netherlands Ministry of Infrastructure and Water Management (Ministerie Van Infrastructuur en Waterstaat), Nissan, OMV, OPEN ENERGI, Renault, Renault Trucks, SEMITAN, Stedin, STEP, Symbio, Toyota, The University of Manchester, WaterstofNet.
This project has received funding from the Fuel Cells and Hydrogen 2 Joint Undertaking under grant agreement No 671438 & No 700350. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, Hydrogen Europe and Hydrogen Europe research.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005025/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom